Recursion Pharmaceuticals (RXRX) Stock Price
$5.28 7.6%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
2 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Recursion Pharmaceuticals, AI stock picks, stock alerts and much more.
RXRX AI Stock Analysis
Financial Performance
Recursion Pharmaceuticals' recent financial performance shows mixed signals. Revenue has shown a significant increase of 226.9% from the previous quarter and a slight increase of 2.3% YoY, which is positive for the company. However, gross profit is negative at -$7.1M, with an alarming decrease of -637.5% YoY, indicating high cost of sales or expenses. The operating income also decreased by -90.3% YoY to -$191.4M, suggesting that the company may be struggling with its operational efficiency.
Stock Price
The stock price currently stands at $5.27, up by 7.1% in the last month but down by -28% YoY, which suggests some recovery but overall bearish trend in the longer term perspective. The RSI value is at a neutral level of 56.72 and the stock's price is below its 200-day moving average ($6.32), indicating potential undervaluation.
Alternative Data Signals
The alternative data signals offer additional insights into Recursion Pharmaceuticals' performance and outlook: Web traffic has decreased slightly (-13.% MoM and -4.% YoY), suggesting less online engagement or interest in their products/services; Job postings have increased significantly (40% MoM), possibly indicating business expansion or higher demand for their products/services; Employee business outlook seems positive but has decreased recently (-12% MoM and -15.% YoY); Social media followers on Twitter have grown substantially in recent months (up by 72.%).
Conclusion
In conclusion, while there are some promising signs such as revenue growth and social media following increase for Recursion Pharmaceuticals, the company's financial performance and stock price trend are concerning. The analysis is somewhat bearish due to negative gross profit and operating income, as well as decreasing web traffic and employee outlook.
Note: This AI Stock Analysis is based on data as of July 05. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
Recursion Pharmaceuticals (RXRX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $5.28, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About RXRX
-
Recursion Pharmaceuticals, Inc.
-
Symbol
RXRX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2.1B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$21.81 0.2% |
8 |
 |
Inovio Pharmaceuticals INO |
$1.36 2.2% |
2 |
 |
Moderna MRNA |
$33.64 1.9% |
3 |
 |
Anavex Life Sciences AVXL |
$11.11 0.6% |
5 |
 |
BridgeBio Pharma BBIO |
$46.47 0.4% |
6 |
News
RXRX Alternative Data
Web Traffic
Recursion Pharmaceuticals receives an estimated 68838 monthly visitors to recursion.com, which is up by 47.5% over the last month.
-
Web Traffic
68838
-
Change from Previous Month
47.5%
-
3 Month Change
13.9%
-
YoY Change
13.9%
Twitter Followers
Recursion Pharmaceuticals has 14,733 Twitter Followers on its main Twitter (also known as X) account, which is up by 1.7% over the last month.
-
Twitter Followers
14733
-
Daily Change
0.1%
-
1 Month Change
1.7%
-
3 Month Change
4.7%
-
YoY Change
4.7%
Facebook Engagement
Recursion Pharmaceuticals has engaged 10 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
10
-
Daily Change
0%
-
1 Month Change
47.4%
-
3 Month Change
33.3%
-
YoY Change
33.3%
Youtube Subscribers
Recursion Pharmaceuticals has 3,930 subscribers on its main Youtube channel, up by 1.8% over the last month.
-
Youtube Subscribers
3930
-
Daily Change
0%
-
1 Month Change
1.8%
-
3 Month Change
11.3%
-
YoY Change
11.3%
Job Postings
Recursion Pharmaceuticals currenly has an estimated 31 open job postings, up by 47.6% over the last month.
-
Job Postings
31
-
Daily Change
0%
-
1 Month Change
47.6%
-
3 Month Change
19.2%
-
YoY Change
19.2%
Reddit Mentions
Recursion Pharmaceuticals has been mentioned an estimated 2 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
2
-
Daily Change
0%
-
1 Month Change
33.3%
-
3 Month Change
60%
Business Outlook
According to employee reviews, the business outlook among employees at Recursion Pharmaceuticals is 66 out of 100 (bullish), down by -12% over the last month.
-
Business Outlook
66
-
Change from Previous Month
12%
-
3 Month Change
9.6%
-
YoY Change
9.6%
News Mentions
Recursion Pharmaceuticals was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Employees
According to LinkedIn, Recursion Pharmaceuticals has 580 employees.
-
LinkedIn Employees
580
-
Daily Change
2%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
RXRX Financials
RXRX Key Metrics
-
Total Revenue
$14.7M
-
Net Income
-$202.5M
-
Earnings per Share
-$0.5
-
Free cash flow
-$133.8M
-
EBITDA
-$191.4M
-
EBITDA Ratio
-12.9785
-
Total Assets
$1.3B
RXRX 2-year Revenue & Income
RXRX 2-year Free Cash Flow
RXRX Technicals
RXRX SMA
RXRX RSI
FAQ
What's the current price of Recursion Pharmaceuticals (RXRX) Stock?
The price of an Recursion Pharmaceuticals (RXRX) share is $5.28.
What's the market cap of Recursion Pharmaceuticals?
The current market cap of Recursion Pharmaceuticals is 2.1B.
Should I buy or sell RXRX?
Recursion Pharmaceuticals shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Recursion Pharmaceuticals is better viewed as a hold or accumulate position while waiting for further developments.
Is Recursion Pharmaceuticals a good investment?
The current analysis of Recursion Pharmaceuticals' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Recursion Pharmaceuticals' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Recursion Pharmaceuticals (RXRX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Recursion Pharmaceuticals stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Recursion Pharmaceuticals (RXRX) that investors often compare it to?
Recursion Pharmaceuticals (RXRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Recursion Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Recursion Pharmaceuticals' stock price to be around $5.25 in 2026. Starting from the current price of $5.28, this represents a 0.6% change in price, indicating a neutral outlook for the stock.
How to buy Recursion Pharmaceuticals (RXRX) Stock?
Recursion Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Recursion Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.